glp 1 ra meds GLP-1 prescription trends: January 2019 – December 2025 Glucagon-like peptide-1 receptor agonists in

However, no objective tumor responses were observed

Now, you might wonder, "If my body makes it, why would I need more?" That's a great question

GLP-1 receptor agonist market is undergoing a structural shift from a diabetes-centric category to one increasingly driven by weight management, with obesity-focused prescribing volumes now matching and, in some segments, surpassing traditional diabetes use

Patients should approach this evidence base with optimism tempered by appropriate uncertainty

10.1146/annurev-med-043021-014919 35 JayaramH.KolkoM.FriedmanD

they might suggest slowing dose increases or adjusting your plan